India, March 19 -- Shares of Black Diamond Therapeutics, Inc. (BDTX) jumped over 27% on Wednesday morning after the clinical-stage oncology company and Servier, an independent global pharmaceutical group, announced a strategic worldwide licensing agreement for BDTX-4933, a therapy for solid tumors.
BDTX is currently trading at $2.1800, up $0.5000 or 27.9762%, on the Nasdaq. The stock opened its trading at $2.3500 after closing Tuesday at $1.6800. The stock has traded between $1.5900 and $7.6600 in the past 52-week period.
Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors.
googletag.cmd.push(fu...